Listed

ICU Medical Inc: Form 10-Q for the period ended Sep 30, 2021

Filed with the SEC on Nov 5, 2021 and accepted by EDGAR at Nov 5, 2021, 17:01 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-07-01 to 2021-09-30$336.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-01-01 to 2021-09-30$975.8mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-07-01 to 2021-09-30$208.3mus-gaap:CostOfRevenue
Cost of revenue9 months2021-01-01 to 2021-09-30$611.8mus-gaap:CostOfRevenue
Gross profit3 months2021-07-01 to 2021-09-30$127.8mus-gaap:GrossProfit
Gross profit9 months2021-01-01 to 2021-09-30$364.0mus-gaap:GrossProfit
Research and development3 months2021-07-01 to 2021-09-30$12.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-01-01 to 2021-09-30$34.3mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-07-01 to 2021-09-30$74.8mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2021-01-01 to 2021-09-30$221.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-07-01 to 2021-09-30$38.4mus-gaap:OperatingIncomeLoss
Operating income9 months2021-01-01 to 2021-09-30$99.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-07-01 to 2021-09-30$168.0kus-gaap:InterestExpense
Interest expense9 months2021-01-01 to 2021-09-30$492.0kus-gaap:InterestExpense
Income tax3 months2021-07-01 to 2021-09-30$6.8mus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-01-01 to 2021-09-30$16.6mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-07-01 to 2021-09-30$31.1mus-gaap:NetIncomeLoss
Net income9 months2021-01-01 to 2021-09-30$83.2mus-gaap:ProfitLoss
Diluted EPS3 months2021-07-01 to 2021-09-30$1.43us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-01-01 to 2021-09-30$3.83us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-07-01 to 2021-09-30$1.47us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-01-01 to 2021-09-30$3.93us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-07-01 to 2021-09-3021,730,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-01-01 to 2021-09-3021,735,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-01-01 to 2021-09-30$184.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-01-01 to 2021-09-30$46.5mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-09-30$519.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-09-30$1.01bnus-gaap:AssetsCurrent
Total assetsAt period end2021-09-30$1.84bnus-gaap:Assets
Current liabilitiesAt period end2021-09-30$185.1mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2021-09-30$1.59bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000883984-21-000033. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.